首页> 外文OA文献 >Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer

【2h】

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer

机译：转移ER + / HER2-乳腺癌的循环肿瘤细胞（CTC）的功能表征揭示了对HER2和FOXM1对内分泌治疗抗性和肿瘤细胞存活的依赖性：对ER + / HER2-乳腺癌的治疗的影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Sven Roßwag; Cristina L. Cotarelo; Klaus Pantel; Sabine Riethdorf; Jonathan P. Sleeman; Marcus Schmidt; Sonja Thaler;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. PIK3CA and ESR1 mutations detected in circulating tumor DNA (ctDNA) are predictive factors for late-line hormone-based therapies in ER+/HER2-metastatic breast cancer (MBC) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：在循环肿瘤DNA（CTDNA）中检测到的PIK3CA和ESR1突变是ER + / HER2-转移性乳腺癌（MBC）的后期激素疗法的预测因素
2. Genomic alterations detected by circulating tumor DNA and correlation with response to treatment with elacestrant, an oral selective estrogen receptor degrader, in phase 1 trials in postmenopausal women with ER+/HER2-advanced/metastatic breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：通过循环肿瘤DNA检测的基因组改变与响应次次口服选择性雌激素受体降解剂的肿瘤DNA和相关性，患有ER + / HER2-先进/转移性乳腺癌的绝经后妇女的1期试验中
3. Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy [J] . Hainsworth John D., Murphy Patrick B., Alemar Jose R., Breast cancer research and treatment. . 2016,第1期

机译：多重免疫测定（PRO Onc测定）在HER2阴性转移性乳腺癌女性循环肿瘤细胞中检测HER2异常：对HER2靶向治疗缺乏反应
4. Evaluation of anti-cancer therapy using in silico analysis of treatments for HER2#x002B; breast cancer [C] . Ganic E., Gundry S., Jianmin Zou, 2014 IEEE International Symposium on Medical Measurements and Applications . 2014

机译：使用计算机分析HER2 +乳腺癌的治疗方法评估抗癌治疗
5. HER2Delta16: a tumor-specific oncogene that drives tumorigenesis and trastuzumab resistance in HER2+ breast cancer. [D] . Huynh, Felicia C. 2015

机译：HER2Delta16：一种肿瘤特异性癌基因，可驱动HER2 +乳腺癌的肿瘤发生和曲妥珠单抗。
6. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients [O] . Shaohua Zhang, Lei Li, Tao Wang, 2016

机译：在组织学上HER2阳性转移性乳腺癌患者中在循环肿瘤细胞上检测到的实时HER2状态预示了抗HER2治疗的不同结果
7. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients [O] . 2016

机译：在组织学上HER2阳性转移性乳腺癌患者中，在循环肿瘤细胞上检测到的实时HER2状态预示了抗HER2治疗的不同结果

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer

著录项

相似文献

相关主题

期刊订阅